Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Prurigo Nodularis: Updates in Clinical Approach & Pathophysiology
Description
The discussion centers around updates in the clinical approach and pathophysiology of Prurigo Nodularis (PN), emphasizing the burden of the disease and its therapeutic options, especially with the recent FDA approval of new treatments like dupilumab. The speakers engage with the audience in a conversational manner, highlighting the complexities of diagnosing and treating PN, mentioning how it often presents differently across demographics, including various skin types. They explore the clinical characteristics of PN, its comorbidities such as diabetes and depression, and the importance of addressing these alongside itch symptoms. Insights into the disease's pathophysiology are discussed, with an emphasis on neurogenic inflammation and the roles of cytokines and immune cells. The conversation touches on the individual treatment strategies using the newly available therapies, noting that effective management is crucial for improving patients' quality of life, especially since many express deep emotional and physical distress due to itch and pain. Emerging therapies are on the horizon, providing hope for more effective management of PN, while the importance of personalized treatment is reiterated as they advocate for proactive and holistic management for patients.
View moreConclusions
- Prurigo nodularis (PN) is associated with a high burden of disease and significant comorbidities.
- Patients with PN often report persistent itching, pain, and sleep disturbances, leading to decreased quality of life.
- Common comorbidities among PN patients include depression, anxiety, sleep disturbance, diabetes, and cardiovascular diseases.
- There is an observed association between prurigo nodularis and various malignancies that warrants careful monitoring.
- The introduction of treatments like dupilumab offers new hope for managing and improving symptoms of PN, with evidence of significant improvements in itch and lesion appearance.
- Eosinophil levels may serve as a predictor for the response to treatments like dupilumab in PN patients.
- A better understanding of the pathophysiology and endotypes of PN is crucial for developing targeted therapies.
- Clinical diagnosis of PN can be complex, necessitating comprehensive evaluations, including laboratory testing to rule out other conditions.
- Cornman et al, Kwatra SG. B J Dermatol. 2024
- Aggarwal et al, Clinical and Experimental Dermatology
- Cornman et al, Kwatra SG. JAAD Int. 2023
- Liao et al, Kwatra SG. B J Dermatol. 2024
- Parthasaranthy et al, Kwatra SG. JAAD. 2023
- Manjunath et al, Kwatra SG. 20th Annual Skin of Color Society Symposium. 2024
- Huang et al. JAAD. 2024
- Yi et al. JAAD. 2024
- Wongvibulsin et al, 2021
- McColl et al, 2021